Publications by authors named "Gadkari A"
Aims: To describe the 12-month effectiveness, persistence, tolerability, and safety of ofatumumab (OMB), a highly effective disease-modifying therapy (DMT) for relapsing multiple sclerosis (MS), in a real-world MS population.
Patients & Methods: Electronic medical records of patients starting OMB from October 2020 to August 2022 at two comprehensive MS centers were reviewed. Demographics and disease characteristics and 6- and 12-month clinical, patient-reported, and radiologic outcome measures were analyzed.
Article Synopsis
- - The study evaluates how well patients stick to their prescribed treatments (persistence and adherence) for the multiple sclerosis medication Ofatumumab (OMB) compared to oral and other self-injectable disease-modifying therapies (DMTs) in a real-world setting from August 2020 to November 2021.
- - Researchers used a retrospective cohort design involving over 11,000 patients, analyzing treatment adherence through measures like the proportion of days covered (PDC) and persistence defined as the time until treatment discontinuation or switch.
- - Results identified two specific patient groups: one using OMB and the other using oral DMTs, enabling a comparison of treatment persistence and adherence between the different therapy types within the study's defined cohorts
Context: Bioceramic sealers have improved sealing ability by forming an interfacial apatite layer that chemically bonds the sealer and radicular dentin thus decrease apical leakage.
Aim: This study aims to evaluate and compare the apical leakage of Cerafill RCS bioceramic sealer and gutta percha when used with three different obturating techniques.
Materials And Methods: Thirty-four extracted single-rooted premolars were decoronated and prepared up to size F3.
Background: Few large-scale international studies have broadly characterized the burden of atopic dermatitis (AD) across age groups among children and adolescents.
Objectives: To better characterize the AD burden in paediatric patients by disease severity.
Methods: This cross-sectional, web-based survey of paediatric patients (6 months to < 18 years old) was conducted in 18 countries representing North America, Latin America, Europe, Middle East/Eurasia and East Asia.
The design of popular disposable electronic cigarettes (ECs) was analyzed, and the concentrations of WS-23, a synthetic coolant, in EC fluids were determined for 22 devices from 4 different brands. All products contained WS-23 in concentrations that ranged from 1.0 to 40.
View Article and Find Full Text PDFAim: 2nd and 3rd generation endoscopic spine surgery techniques offer visualisation of familiar inter-laminar anatomy to spinal surgeons. We have prospectively evaluated the clinical outcome, complications and learning curve associated with these techniques in patients with lumbar spine radiculopathy.
Methods: This is a prospective study of 50 consecutive patients with radicular pain from disc herniation and/or lateral recess stenosis.
Needle Cap External Fixator for Proximal Phalanx Fracture - A Case Report.
J Orthop Case Rep
October 2022
Introduction: Among all the phalanges, most fractured is the proximal phalanx. Frequently encountered complications are malunion, stiffness, and soft-tissue injury which invariably increase the disability. The aim of fracture reduction, therefore, comprises acceptable alignment and the gliding of the flexor and extensor tendons are maintained.
View Article and Find Full Text PDFBackground: Grisel's syndrome is a nontraumatic atlantoaxial subluxation resulting from an ongoing local inflammatory process.
Case Description: An 8-year-old male presented to the emergency department with neck pain which was sudden in onset without any history of any significant fall or trauma. On physical examination, the patient had torticollis with a head tilt to the left side and the chin rotated to the right.
Correlation of pelvic incidence and pelvic parameters in lumbar spondylolisthesis.
Surg Neurol Int
September 2022
Background: Pelvic incidence (PI) and pelvic parameters (PP) regulate the sagittal alignment of the spine and the pelvis in normal populations. Correlation of PI even more so than PP with lumbar spondylolisthesis (LS) would be useful for surgical planning.
Methods: This study included 45 patients randomly selected with LS.
Introduction: Itch associated with atopic dermatitis (AD) has a profoundly negative effect on patients of all ages. Therefore, itch is a main target for AD therapeutic approaches, and treatments are perceived as beneficial when they achieve an itch reduction. In the absence of a validated scale for children aged 6-11 years that is suitable for assessing itch intensity in clinical trial settings, the Worst Itch Scale was developed.
View Article and Find Full Text PDFBackground: Posterior element involvement of the spine with tuberculosis (TB) is very uncommon.
Case Description: A 25-year-old immunocompetent female presented with dull mid-back ache and tenderness over the inferior angle of the left scapula and left 7 costovertebral junction. The MRI showed erosion and enhancing soft tissue in the periarticular region of the left 7 costotransverse joint.
Objective: To evaluate the impact of atopic dermatitis on families of pediatric patients.
Study Design: This cross-sectional, web-based survey of children/adolescents (6 months to <18 years old) with atopic dermatitis and their parents and caregivers was conducted in 18 countries encompassing North America, Latin America, Europe, Middle East/Eurasia, and East Asia. Children and adolescents with atopic dermatitis and their parents and caregivers were identified by the International Study of Asthma and Allergies in Childhood criteria and ever being told by a physician that they had "eczema".
Importance: Clinical trial populations may not reflect clinical practice: knowledge generated in other settings can inform clinical decision-making.
Objective: To evaluate self-reported disease control and quality of life after initiating dupilumab treatment in patients with atopic dermatitis (AD) in the the clinical setting.
Design, Setting, And Participants: This cohort study using an online survey administered prior to (baseline) and at 1, 2, 3, 6, 9, and 12 months after dupilumab initiation included adults with moderate-to-severe AD who initiated treatment with dupilumab through the US patient support program and agreed to participate in the study.
Introduction: Atopic dermatitis (AD) is a systemic inflammatory condition that may increase the risk of cardiovascular disease (CVD); however, ongoing debate exists surrounding its direct association. We aimed to elucidate whether AD contributes to a higher incidence of CVD and major adverse cardiovascular events (MACE) in adult patients with AD, independent of metabolic disorders.
Methods: We retrospectively analyzed a large US-based population of patients with AD (≥ 18 years of age).
Dupilumab Improves Asthma and Sinonasal Outcomes in Adults with Moderate to Severe Atopic Dermatitis.
J Allergy Clin Immunol Pract
March 2021
Background: Dupilumab has demonstrated efficacy with acceptable safety in clinical trials in patients with moderate to severe atopic dermatitis (AD).
Objective: To assess dupilumab's impact on asthma and sinonasal conditions in adult patients with moderate to severe AD in four randomized, double-blinded, placebo-controlled trials.
Methods: In LIBERTY AD SOLO 1 (NCT02277743), SOLO 2 (NCT02755649), CHRONOS (NCT02260986), and CAFÉ (NCT02755649), patients received placebo, dupilumab 300 mg every 2 weeks (q2w), or dupilumab 300 mg weekly (qw).
Background: Little is known on the current global prevalence of atopic dermatitis (AD) in the pediatric population.
Objective: To estimate the real-world global prevalence of AD in the pediatric population and by disease severity.
Methods: This international, cross-sectional, web-based survey of children and adolescents (6 months to <18 years old) was conducted in the following 18 countries: North America (Canada, United States), Latin America (Argentina, Brazil, Columbia, Mexico), Europe (France, Germany, Italy, Spain, United Kingdom), Middle East and Eurasia (Israel, Saudi Arabia, Turkey, United Arab Emirates, Russia), and East Asia (Japan, Taiwan).
Background: The Harmonising Outcome Measures for Eczema (HOME) initiative has established a core outcome set of domains for atopic eczema (AE) clinical trials. Previous consensus meetings have agreed on preferred instruments for clinician-reported signs (Eczema Area and Severity Index, EASI) and patient-reported symptoms (Patient-Oriented Eczema Measure, POEM). This paper reports consensus decisions from the HOME VII meeting.
View Article and Find Full Text PDFBackground: An estimated 50% of children in the US are Medicaid-insured. Some of these patients have poor health literacy and limited access to medications and specialty care. These factors affect treatment utilization for pediatric patients with atopic dermatitis (AD), the most common inflammatory skin disease in children.
View Article and Find Full Text PDFBackground: The Harmonising Outcome Measures for Eczema (HOME) initiative has established a core outcome set of domains for atopic eczema clinical trials. Previous consensus meetings have agreed upon preferred instruments for clinician-reported signs (Eczema Area and Severity Index - EASI) and patient-reported symptoms (Patient-Oriented Eczema Measure - POEM). This paper reports consensus decisions from the HOME VII meeting.
View Article and Find Full Text PDFDeveloping a laboratory model of oral polymicrobial communities is essential for in vitro studies of the transition from healthy to diseased oral plaque. SHI medium is an enriched growth medium capable of supporting in vitro biofilms with similar diversity to healthy supragingival inocula; however, this medium does not maintain the diversity of gram-negative bacteria more associated with subgingival plaque. Here, we systematically modified SHI medium components to investigate the impacts of varying nutrients and develop a medium capable of supporting a specific disease-state subgingival community.
View Article and Find Full Text PDFBackground: Pain is a frequent symptom of atopic dermatitis (AD).
Objectives: The aims of the study were to evaluate the effects of dupilumab on pain/discomfort in AD and to determine whether pain correlates with other outcomes.
Methods: This was a post hoc analysis of 5 randomized, placebo-controlled clinical trials in which adults with chronic AD received placebo or dupilumab 300 mg every 2 weeks or once weekly with and without topical corticosteroids.
Background: Dupilumab has demonstrated efficacy and acceptable safety in adults and children (aged 6-17 years) with moderate-to-severe atopic dermatitis (AD), but effective systemic therapy with a favorable risk-benefit profile in younger children remains a significant unmet need.
Objectives: To determine the pharmacokinetics, safety and efficacy of single-dose dupilumab in children with severe AD aged ≥6 months to <6 years.
Methods: This open-label, multicenter, phase 2, sequential, two-age cohort, two-dose level study (LIBERTY AD PRE-SCHOOL; NCT03346434) included an initial cohort of older children aged ≥2 to <6 years, followed by a younger cohort aged ≥6 months to <2 years.
Real-world persistence with dupilumab among adults with atopic dermatitis.
Ann Allergy Asthma Immunol
January 2021
Background: The real-world persistence with dupilumab therapy for atopic dermatitis (AD) is unknown.
Objective: To characterize adults with AD who initiated dupilumab and evaluate persistence with dupilumab therapy.
Methods: This retrospective cohort study used the IBM MarketScan Commercial and Medicare database.